Clarivate Seeks Up to $500 Million of 2028 and 2029 Notes for Cash

Clarivate Plc (CLVT ) announced on November 4, 2026 that its wholly owned subsidiary, Clarivate Science Holdings Corporation, had commenced separate cash tender offers for up to US$500 million in aggregate principal of its 3.875% Senior Secured Notes due July 1, 2028 and 4.875% Senior Notes due July 1, 2029.

Accepted notes will be retired and canceled, and Clarivate intends to fund the purchases with cash on hand. The Offer to Purchase divides the overall limit into as much as $400 million principal of the 2028 notes and $100 million of the 2029 notes. Those caps compare with $750 million and $900 million outstanding, respectively, so neither offer seeks to retire an entire series.

Pricing Differs Between the Two Series

Accepted holders in either series will receive accrued and unpaid interest from the preceding interest payment date to, but excluding, settlement, on top of the total consideration. For the 2029 notes, that consideration is fixed at $928.75 per $1,000 principal.

The 2028 notes instead use a market-based price. Their offer yield will equal the yield on the 4.125% U.S. Treasury security due June 30, 2028 plus 50 basis points, measured at 2:00 p.m. New York City time on November 10, 2026. Discounting the notes’ remaining payments at that yield determines the consideration, meaning the launch documents do not provide a fixed 2028 purchase price.

Both offers are scheduled to expire at 5:00 p.m. that day, which is also the withdrawal deadline. Settlement is expected on November 13, 2026 unless an offer is extended. Tenders exceeding a series cap will be subject to proration, with unaccepted principal returned to holders. Neither offer requires a minimum aggregate principal amount to be tendered or completion of the other offer, leaving the final accepted amounts uncertain until after expiration.

Previous 2028 Tender Was Heavily Oversubscribed

The final results from Clarivate’s separate September 2026 tender show how its previous cap affected allocations. The 2028 series had $825 million principal outstanding before that transaction, and holders validly tendered $665.198 million against a maximum purchase amount of $75 million.

Clarivate accepted only $75 million, producing an 11.3% proration factor, and paid total consideration of $975.15 per $1,000 principal. The new offer revisits the same series with a substantially larger cap, but its price will not be established until the reference-yield measurement. September’s price therefore provides a historical comparison rather than the terms available to tendering holders now.

Debt Reduction Follows Earlier Repurchases and an Asset Sale

Clarivate’s third-quarter results supply the balance-sheet backdrop. Total debt outstanding was $4.1761 billion at September 30, 2026, down $293.8 million compared with the prior year. The reduction reflected a $100 million January repayment that fully redeemed senior secured notes due November 2026, together with the retirement of $192.6 million principal of 2028 and 2029 notes through repurchases at an approximate 5% discount to par. Cash and cash equivalents, including restricted cash, were $257 million at September 30. Clarivate subsequently completed the Life Sciences & Healthcare sale on October 6 for net cash proceeds of $488.4 million, while the tender identifies its funding simply as cash on hand. Third-quarter net interest expense of $61 million exceeded operating income from continuing operations of $40.1 million, underscoring the scale of financing costs relative to operating earnings.

The offers’ balance-sheet effect will become clear only after Clarivate reports the accepted amounts. Notes left unpurchased will remain outstanding on unchanged terms. However, the offer document cautions that reducing either unlisted series could produce a more limited trading market, making liquidity in the remaining debt part of the transaction’s consequences alongside the principal retired.